[go: up one dir, main page]

MX9200992A - Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion. - Google Patents

Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.

Info

Publication number
MX9200992A
MX9200992A MX9200992A MX9200992A MX9200992A MX 9200992 A MX9200992 A MX 9200992A MX 9200992 A MX9200992 A MX 9200992A MX 9200992 A MX9200992 A MX 9200992A MX 9200992 A MX9200992 A MX 9200992A
Authority
MX
Mexico
Prior art keywords
ethyl
methyl
pharmaceutical composition
active ingredient
methanosulfonamide
Prior art date
Application number
MX9200992A
Other languages
English (en)
Inventor
Anthony John Phillips
Ian Keith Winterborn
John Malcolm Padfield
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX9200992A publication Critical patent/MX9200992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Waveguide Aerials (AREA)
  • Non-Reversible Transmitting Devices (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
MX9200992A 1991-03-08 1992-03-06 Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion. MX9200992A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919104890A GB9104890D0 (en) 1991-03-08 1991-03-08 Compositions

Publications (1)

Publication Number Publication Date
MX9200992A true MX9200992A (es) 1992-09-01

Family

ID=42342461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9200992A MX9200992A (es) 1991-03-08 1992-03-06 Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.

Country Status (29)

Country Link
US (4) US5863559A (es)
EP (1) EP0503440B1 (es)
JP (1) JP2986546B2 (es)
KR (1) KR100202042B1 (es)
AT (1) ATE165973T1 (es)
AU (1) AU663303B2 (es)
BE (1) BE1005086A5 (es)
CA (1) CA2105180C (es)
CH (1) CH684242A5 (es)
CY (1) CY2011A (es)
CZ (1) CZ282352B6 (es)
DE (1) DE69225421T2 (es)
DK (1) DK0503440T3 (es)
ES (1) ES2117015T3 (es)
FR (1) FR2673538B1 (es)
GB (2) GB9104890D0 (es)
GE (1) GEP20012549B (es)
HK (1) HK19395A (es)
IE (1) IE920726A1 (es)
IL (1) IL101162A (es)
IT (1) IT1271495B (es)
MX (1) MX9200992A (es)
NL (1) NL9200423A (es)
NZ (1) NZ241873A (es)
OA (1) OA09812A (es)
RU (1) RU2098093C1 (es)
SG (1) SG169294G (es)
WO (1) WO1992015295A1 (es)
ZA (1) ZA921690B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
DE4314976C1 (de) * 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9924717D0 (en) * 1999-10-19 1999-12-22 Glaxo Group Ltd Diagnostic
AT500063A1 (de) 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
CN1681493A (zh) * 2002-07-19 2005-10-12 兰贝克赛实验室有限公司 掩味舒马曲坦片剂及其制备方法
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
KR20060015641A (ko) * 2003-06-06 2006-02-17 글락소 그룹 리미티드 트립탄 및 ｎｓａｉｄ를 포함하는 조성물
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
WO2005115345A1 (en) * 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1765300A2 (en) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US8283478B2 (en) 2005-05-20 2012-10-09 Janssen Pharmaceutica Nv Process for preparation of sulfamide derivatives
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
ATE502921T1 (de) 2006-10-19 2011-04-15 Auspex Pharmaceuticals Inc Substituierte indole
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
CN102088966B (zh) * 2008-06-20 2015-06-10 阿尔法制药有限公司 药物制剂
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
WO2010005507A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2016141056A1 (en) 2015-03-02 2016-09-09 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions

Also Published As

Publication number Publication date
US6368627B1 (en) 2002-04-09
JPH06505020A (ja) 1994-06-09
BE1005086A5 (fr) 1993-04-13
DE69225421T2 (de) 1998-10-15
GB2254784B (en) 1994-11-16
AU1326492A (en) 1992-10-06
IE920726A1 (en) 1992-09-09
EP0503440B1 (en) 1998-05-13
FR2673538B1 (fr) 1995-05-12
GEP20012549B (en) 2001-10-25
ZA921690B (en) 1993-08-02
IL101162A (en) 1997-11-20
DK0503440T3 (da) 1999-01-18
IL101162A0 (en) 1992-11-15
ITRM920155A0 (it) 1992-03-06
NZ241873A (en) 1994-06-27
CA2105180A1 (en) 1992-09-09
GB9204761D0 (en) 1992-04-15
AU663303B2 (en) 1995-10-05
CY2011A (en) 1998-02-20
CH684242A5 (fr) 1994-08-15
GB2254784A (en) 1992-10-21
OA09812A (en) 1994-04-15
IT1271495B (it) 1997-05-30
ATE165973T1 (de) 1998-05-15
NL9200423A (nl) 1992-10-01
DE69225421D1 (de) 1998-06-18
EP0503440A1 (en) 1992-09-16
ES2117015T3 (es) 1998-08-01
CA2105180C (en) 1999-08-17
JP2986546B2 (ja) 1999-12-06
SG169294G (en) 1995-04-28
US20020197318A1 (en) 2002-12-26
US5863559A (en) 1999-01-26
CZ184993A3 (en) 1994-06-15
GB9104890D0 (en) 1991-04-24
HK19395A (en) 1995-02-17
CZ282352B6 (cs) 1997-07-16
US6020001A (en) 2000-02-01
WO1992015295A1 (en) 1992-09-17
RU2098093C1 (ru) 1997-12-10
FR2673538A1 (fr) 1992-09-11
ITRM920155A1 (it) 1993-09-06
KR100202042B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
RU93057724A (ru) Фармацевтическая композиция, способ ее получения и способ лечения
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
DE60003160D1 (de) Kombinationen von formoterol und mometasonfuroat
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
TR200103144T2 (tr) Yeni bileşikler
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
ATE347357T1 (de) Zusammensetzungen, welche tetracycline enthalten, zur behandlung oder verhinderung von mukositis
KR927003530A (ko) 이온삼투요법용 제약 제제의 제조에 있어서의 국소 마취제의 용도
AR025498A1 (es) Una nueva asociacion farmaceutica que presenta un efecto analgesico

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees